EU approval of the Danish company’s alcohol-pill, Selincro, would send a great signal, as the company would gain be gaining approval for drugs that can help it traverse an impending patent cliff, says Sydbank’s stock market analyst and pharmaceutical expert, Søren Løntoft Hansen. But he is not quite as positive as Lundbeck when it comes to expectations for annual European sales.
“Lundbeck expects a top sales potential of 2.5 billion kroner (442 million USD). My estimate is somewhat lower, and I think the same goes for my colleagues. We want to wait and see how sales develop. My top sales estimate is at 1.4 billion kroner (247 million USD). But you can safely say that the pill has a potential of more than a billion,” he tells Medwatch.